Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Researchers in Canada report progress in crafting a vaccine containing 10 different proteins that could prevent hepatitis C infectionless likely to adhere to their anti-HIV drug regimens than those only infected with HIV, according to a study in the February 14 edition of the journal AIDS. Canadian researchers, studying 1,186 HIVers found that HCV coinfection was a risk factor for adherence failure, defined as taking less than 95% of anti-HIV medications as prescribed. Male HIVers also were less likely to be adherent. An increase in ribavirin dosage may help improve responses to hepatitis C treatment in HIV-HCV coinfected adults, according to studies presented at the Second International Workshop on HIV and Hepatitis C Coinfection. Adjusting the dosage of ribavirin'marketed as Copegus, Rebetol, and Virazole'based on a patient's weight is more effective in controlling HCV than standard 800-milligram-per-day dosing, according to French researchers. Fatigue is commonly misdiagnosed as depression among HIV-HCV coinfected patients receiving anti-hepatitis drugs, according to a study by New York researchers. Depression is a common psychological side effect of hepatitis C therapy and a major reason treatment is halted. But the scientists reported at the Second International Workshop on HIV and Hepatitis C Coinfection that fatigue, usually caused by anemia, is more than twice as prevalent during HCV treatment than depression, but is commonly misdiagnosed. Measuring levels of ALT, an enzyme that is a marker of liver function, may be an inaccurate gauge of liver disease in HIV-HCV coinfected adults, according to a study in the January 1 edition of the Journal of Acquired Immune Deficiency Syndromes. Researchers found that 25% of patients with normal ALT levels actually had such severe liver damage that they required hepatitis treatment, with 13% having developed cirrhosis-related liver scarring. A study of 50 Spanish HIV patients who've undergone liver transplants due to hepatitis coinfection shows that the procedure is safe and effective in the short- and mid-term. The study showed that survival rates were 85% after one year, 75% after two years, and 66% after three years, levels similar to those seen in HIV-negative hepatitis patients who received liver transplants. Long-term success of hepatitis C therapy among HIV-HCV coinfected adults can be predicted by the early response to anti-hepatitis drugs after just four weeks of treatment, according to a study presented at the 13th Conference on Retroviruses and Opportunistic Infections. Among study patients who achieved a rapid virologic response to the medications, 95% maintained viral suppression through 24 weeks of treatment and 90% maintained suppression for at least another 24 weeks after drug therapy was stopped. Among those with a slower response to the drugs, only 69% achieved viral control by the end of the 24-week treatment period and only 37% maintained virologic suppression through the 24-week post-treatment follow-up.
From our Sponsors
Most Popular
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
The freedom of disclosure: David Anzuelo's journey through HIV, art, and advocacy
August 02 2024 12:21 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
Plus: Featured Video
Latest Stories
Meet our Health Hero of the Year, Armonté Butler
October 21 2024 12:53 PM
AIDS/LifeCycle is ending after more than 30 years
October 17 2024 12:40 PM
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
October 15 2024 5:03 PM
How fitness coach Tyriek Taylor reclaims his power from HIV with self-commitment
September 19 2024 12:00 PM
Out100 Honoree Tony Valenzuela thanks queer and trans communities for support in his HIV journey
September 18 2024 12:00 PM
Kentucky bans conversion therapy for youth as Gov. Andy Beshear signs 'monumental' order
September 18 2024 11:13 AM
Why activist Raif Derrazi thinks his HIV diagnosis is a gift
September 17 2024 12:00 PM
Creator and host Karl Schmid fights HIV stigma with knowledge
September 12 2024 12:03 PM
Study finds use of puberty blockers safe and reversible, countering anti-trans accusations
September 11 2024 1:11 PM
Latinx health tips / Consejos de salud para latinos (in English & en espanol)
September 10 2024 4:29 PM
The Trevor Project receives $5M grant to support LGBTQ+ youth mental health in rural Midwest (exclusive)
September 03 2024 9:30 AM
Introducing 'Health PLUS Wellness': The Latinx Issue!
August 30 2024 3:06 PM
La ciencia detrás de U=U ha estado liberando a las personas con VIH durante años
August 23 2024 2:48 PM
Tratamiento y prevención del VIH por inyección: Todo lo que necesita saber
August 23 2024 2:41 PM
Sr. Gay World quiere asegurarse de que estés bien
August 23 2024 2:30 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
With a new case in Sweden, what is the new mpox outbreak and should you be concerned?
August 15 2024 4:48 PM
From ‘The Real World’ to real life: How Danny Roberts thrives with HIV
July 31 2024 5:23 PM